Oculis has raised 20 million Swiss francs, or $20.3 million, in Series B financing for the clinical development of OC-118 for the treatment of diabetic macular edema, according to a press release.
The financing was led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners, and also included existing investors Brunnur Ventures and Silfurberg.
OC-118, developed using Oculis’ solubilizing nanoparticle technology platform, is currently in a phase 2b clinical trial for the treatment of DME and in prior pilot studies showed a “statistically significant and clinical
Uncategorized